Vaccines (Feb 2017)

Harnessing Nanoparticles for Immunomodulation and Vaccines

  • Ariane C. Gomes,
  • Mona Mohsen,
  • Martin F. Bachmann

DOI
https://doi.org/10.3390/vaccines5010006
Journal volume & issue
Vol. 5, no. 1
p. 6

Abstract

Read online

The first successful use of nanoparticles (NPs) for vaccination was reported almost 40 years ago with a virus-like particle-based vaccine against Hepatitis B. Since then, the term NP has been expanded to accommodate a large number of novel nano-sized particles engineered from a range of materials. The great interest in NPs is likely not only a result of the two successful vaccines against hepatitis B and Human Papilloma Virus (HPV) that use this technology, but also due to the versatility of those small-sized particles, as indicated by the wide range of applications reported so far, ranging from medicinal and cosmetics to purely technical applications. In this review, we will focus on the use of NPs, especially virus-like particles (VLPs), in the field of vaccines and will discuss their employment as vaccines, antigen display platforms, adjuvants and drug delivery systems.

Keywords